InvestorsHub Logo
Followers 3
Posts 13
Boards Moderated 0
Alias Born 10/31/2023

Re: None

Saturday, 11/04/2023 6:52:17 PM

Saturday, November 04, 2023 6:52:17 PM

Post# of 5639
Don't know about ocgn’s Operation Next Gen product, how it will perform or why we were chosen to be a part of Next Gen? Below are some important facts and links.

Phase 3 safety study for our ChAd vector vaccine via Nasal delivery:

https://www.nature.com/articles/s41541-023-00717-8

Phase 3 trial for our Inhalation delivery device:

https://www.prnewswire.com/news-releases/convidecia-phase-iii-results-published-in-the-lancet-301450673.html

Phase1 efficacy results using both our ChAd vector vaccine and our inhalation delivery device.
Quote- "so efficient at targeting the lungs and upper airways that it can achieve maximum protection with a small fraction of the dose of current vaccines - possibly as little as 1 per cent - meaning a single batch of vaccine could go 100 times farther, the researchers say.”

https://brighterworld.mcmaster.ca/articles/researchers-confirm-newly-developed-inhaled-vaccine-delivers-broad-protection-against-sars-cov-2-variants-of-concern/
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OCGN News